Chacko Jacob
Chacko Jacob's purchase track record
Chacko Jacob has only 2 open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 5/11/2022 | ORIC | $1.29M | +71.8% | -3.3% | -4.7% |
| 3/23/2022 | ORIC | $1.72M | -15.2% | -31.5% | -14.9% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
FDMT listed in Benzinga pre-market movers. 4D Molecular Therapeutics was mentioned in a Benzinga report on stocks moving lower in Friday’s pre-market session. The article grouped FDMT with other companies like Scholastic and Zscaler, noting a generally downbeat tone among legacy education and other large-cap names. This indicates the stock was part of a broader market movement rather than reacting to a company-specific announcement.
Transaction History
| ORIC | ▼ Sell | Open Market | 33,374 | $302K | 12/16/2025 | View on chart |
| ORIC | ▲ Buy | Option Exercise | 83,666 | $0 | 12/15/2025 | View on chart |
| ORIC | ▼ Sell | Open Market | 37,461 | $462K | 10/6/2025 | View on chart |
| ORIC | ▼ Sell | Open Market | 53,001 | $639K | 10/1/2025 | View on chart |
| ORIC | ▼ Sell | Open Market | 34,538 | $415K | 9/30/2025 | View on chart |
| ORIC | ▼ Sell | Open Market | 125,000 | $1.3M | 9/22/2025 | View on chart |
| ORIC | ▼ Sell | Open Market | 24,660 | $204K | 12/16/2024 | View on chart |
| ORIC | ▲ Buy | Option Exercise | 67,000 | $0 | 12/15/2024 | View on chart |
| ORIC | ▼ Sell | Open Market | 40,000 | $648K | 3/6/2024 | View on chart |
| ORIC | ▼ Sell | Open Market | 26,042 | $320K | 2/7/2024 | View on chart |
| ORIC | ▼ Sell | Open Market | 13,958 | $169K | 2/6/2024 | View on chart |
| ORIC | ▲ Buy | Option Exercise | 38,667 | $0 | 12/15/2023 | View on chart |
| ORIC | ▼ Sell | Open Market | 14,539 | $125K | 12/15/2023 | View on chart |
| ORIC | ▼ Sell | Open Market | 5,156 | $41K | 7/11/2023 | View on chart |
| ORIC | ▼ Sell | Open Market | 10,508 | $84K | 7/10/2023 | View on chart |
| ORIC | ▼ Sell | Open Market | 4,336 | $35K | 7/5/2023 | View on chart |
| ORIC | ▼ Sell | Open Market | 20,000 | $161K | 6/26/2023 | View on chart |
| FDMT | ▲ Buy | Option Exercise | 5,000 | $47K | 4/21/2023 | View on chart |
| FDMT | ▼ Sell | Open Market | 5,000 | $100K | 4/21/2023 | View on chart |
| ORIC | ▲ Buy | Option Exercise | 16,666 | $0 | 12/15/2022 | View on chart |
| ORIC | ▼ Sell | Open Market | 5,764 | $19K | 12/15/2022 | View on chart |
| ORIC | ▲ Buy | Open Market | 76,072 | $215K | 5/13/2022 | View on chart |
| ORIC | ▲ Buy | Open Market | 69,354 | $190K | 5/12/2022 | View on chart |
| ORIC | ▲ Buy | Open Market | 304,574 | $884K | 5/11/2022 | View on chart |
| ORIC | ▲ Buy | Open Market | 50,000 | $227K | 3/25/2022 | View on chart |
| ORIC | ▲ Buy | Open Market | 42,873 | $216K | 3/24/2022 | View on chart |
| ORIC | ▲ Buy | Open Market | 257,127 | $1.3M | 3/23/2022 | View on chart |
| ORIC | ▼ Sell | Open Market | 3,736 | $94K | 9/15/2021 | View on chart |
| ORIC | ▼ Sell | Open Market | 4,420 | $111K | 9/14/2021 | View on chart |
| ORIC | ▼ Sell | Open Market | 2,801 | $70K | 9/13/2021 | View on chart |
| ORIC | ▼ Sell | Open Market | 2,942 | $74K | 9/10/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 15, 2026
JP Morgan Upgrades ORIC, Raises Target to $26
JP Morgan has upgraded ORIC to Overweight and lifted its price target to $26, reflecting confidence in the company’s pipeline. A recent Yahoo article questions whether ORIC’s off‑balance‑sheet funding for project ORIC‑259 changes its R&D risk profile. These developments add new context to the stock’s current technical position near its 200‑day SMA and a support level of $8.69.
JP Morgan Upgrades ORIC, Raises Target to $26. JP Morgan has upgraded ORIC to Overweight and lifted its price target to $26, reflecting confidence in the company’s pipeline. A recent Yahoo article questions whether ORIC’s off‑balance‑sheet funding for project ORIC‑259 changes its R&D risk profile. These developments add new context to the stock’s current technical position near its 200‑day SMA and a support level of $8.69.